- Home
- IMMX vs KUKE Comparison
IMMX vs KUKE Comparison
Compare IMMX & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- KUKE
- Stock Information
- Founded
- IMMX 2014
- KUKE 2002
- Country
- IMMX United States
- KUKE China
- Employees
- IMMX N/A
- KUKE N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- KUKE Other Consumer Services
- Sector
- IMMX Health Care
- KUKE Real Estate
- Exchange
- IMMX Nasdaq
- KUKE Nasdaq
- Market Cap
- IMMX 51.1M
- KUKE 49.8M
- IPO Year
- IMMX 2021
- KUKE 2021
- Fundamental
- Price
- IMMX $1.66
- KUKE $0.74
- Analyst Decision
- IMMX Strong Buy
- KUKE
- Analyst Count
- IMMX 1
- KUKE 0
- Target Price
- IMMX $7.00
- KUKE N/A
- AVG Volume (30 Days)
- IMMX 125.2K
- KUKE 463.8K
- Earning Date
- IMMX 11-11-2024
- KUKE 10-15-2024
- Dividend Yield
- IMMX N/A
- KUKE N/A
- EPS Growth
- IMMX N/A
- KUKE N/A
- EPS
- IMMX N/A
- KUKE N/A
- Revenue
- IMMX N/A
- KUKE $15,080,878.00
- Revenue This Year
- IMMX N/A
- KUKE N/A
- Revenue Next Year
- IMMX $200.00
- KUKE N/A
- P/E Ratio
- IMMX N/A
- KUKE N/A
- Revenue Growth
- IMMX N/A
- KUKE N/A
- 52 Week Low
- IMMX $1.26
- KUKE $0.48
- 52 Week High
- IMMX $7.75
- KUKE $4.07
- Technical
- Relative Strength Index (RSI)
- IMMX 45.76
- KUKE 39.95
- Support Level
- IMMX $1.43
- KUKE $0.72
- Resistance Level
- IMMX $1.94
- KUKE $0.85
- Average True Range (ATR)
- IMMX 0.13
- KUKE 0.10
- MACD
- IMMX -0.01
- KUKE 0.01
- Stochastic Oscillator
- IMMX 57.97
- KUKE 39.43
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About KUKE Kuke Music Holding Limited each representing one
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.